New

Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

Compare ETFs Easily

The Ultimate ETF Comparison Tool - Try Now!

Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.

›ETF Providers›L&G›BIGT

BIGT ETF · L&G Pharma Breakthrough UCITS ETF

The BIGT Exchange Traded Fund (ETF) is provided by L&G. It is built to track an index: Solactive Pharma Breakthrough Value Index. The BIGT ETF provides physical exposure, so by buying it you actually own parts of all the 36 underlying holdings. The dividend policy is capitalization.
Last update 4/2/2026, 7:00 AM UTC
LIVE
CLOSED
This fund is part ofWorld Blended Cap1M perf.-5.01%
Last price
£1,036.00
1M perf.
+0.16%
1M flows
-€567K
AuM
€17M
E/R
0.49%
Rating
ESG Consensus®
esg grade icon
BIGT
£1,036.00

Performance & flows

Segment for quartile rank
January 2, 2026 → April 2, 2026
0-6-4-2024%FEBMARAPRFEBMARAPR
Create a free account to view the flows graph
BIGT
$13.72
+0.36%
World Blended Cap
-1.13%

Historic performance and flows

1M3M1Y3Y5YMTDQTDYTD
Perf.
+0.16%
icon
+0.36%
icon
+32.08%
icon
+22.36%
icon
+10.54%
icon
+1.97%
+1.97%
+0.51%
icon
Flows

Key fund info

Segment for quartile rank
Main characteristics
Issuer
ISIN
IE00BF0H7608
AuM
€17M
icon
E/R
0.49%
icon
Replication rating
icon
ESG Consensus®
esg grade icon
icon
More details
NAV
4/2/2026
$13.72
1D NAV change
-0.36%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
36
Inception date
1/23/2018
Jurisdiction
Ireland
Distribution
Switzerland
Finland
Netherlands
Norway
Spain
Legal structure
Open-end Investment Company
Base currency
USD
Classification
Product type
Benchmark
Solactive Pharma Breakthrough Value Index
Asset class
Factors
N/A
Investment strategy
The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
half moonhalf moon double
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
See all Trackinsight Enterprise features

Trackinsight
Enterprise

Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight Enterprise

Advertisement

Risk profile

Segment for quartile rank

Historical risk/return profile

3M1Y3Y5Y
Returns
+0.36%
icon
+32.08%
icon
+22.36%
icon
+10.54%
icon
Volatility
Perf./Volatility
Max drawdown
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
1
2
3
4
5
6
7
PRIIPS
1
2
3
4
5
6
7
More exposure metrics are available, exclusively in Trackinsight Enterprise

Exposure

Countries
USA
62.80%
Japan
11.97%
Sweden
3.80%
France
3.25%
United Kingdom
3.12%
Republic of Korea
2.89%
Switzerland
2.85%
Netherlands
2.71%
Denmark
2.60%
Other
3.98%
Sectors
Health Care
87.25%
Materials
2.89%
Unavailable
9.86%
Diversification
Total weight of top 15 holdings out of 36
Top 15 holdings
Data as of February 28, 2026
SWEDISH ORPHAN BIOVITRUM
NIPPON SHINYAKU
CHUGAI PHARMACEUTICAL
TRAVERE THERAPEUTICS INC
BIOGEN INC
MIRUM PHARMACEUTICALS INC
IONIS PHARMACEUTICALS INC
XENCOR INC/D
Create a free account to view top holdings
IPSEN PROMESSES
BRIDGEBIO PHARMA
ROYALTY PHARMA
PTC THERAPEUTI/D
VERTEX PHARMACEUTICALS
CATALYST PHARMACEUTICALS INC
UTD THERAPEUT
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise

Sustainability

Integrates ESG criteria
Yes
SDG

ESG Consensus® by Conser

Data as of December 31, 2025
Methodology

Our partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about BIGT ETF's sustainability, based on their methodology.

Learn more about Conser

ESG Consensus®
esg grade icon

ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.


BIGT’s has a Final Sustainability Grade of either B+, B, or B-.

This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight Enterprise
Holdings review
82.18% of holdings have positive scoring
17.85% of holdings have negative scoring
8.74%
55.16%
18.29%
5.99%
11.85%
Consensus levels
Strong
Medium
Weak
More sustainability metrics are available, exclusively in Trackinsight Enterprise

Replication

Trackinsight replication rating:
Replication quality
Calculated over 12m, as of March 31, 2026
Tracking error
Tracking difference
Replication information
Index
Solactive Pharma Breakthrough Value NTR Index - USD
Index ticker
SOLBIOT Index
Index dividend policy
NTR
Replication method
Replication model
More replication analysis are available, exclusively in Trackinsight Enterprise

Issuer

L&G
L&G ID Card
Number of funds
72
Total AuM
€20.72B
Expense ratio range
0.05% - 0.8%
Average expense ratio
0.3324%

Frequently asked questions about BIGT

What does L&G Pharma Breakthrough UCITS ETF, BIGT, invest in?

BIGT is a Passive ETF. This ETF provides exposure to Other Equities.

Which benchmark or index does BIGT replicate?

BIGT tracks the Solactive Pharma Breakthrough Value NTR Index - USD, through a full replication replication method.

What is the Total Expense ratio (TER) of BIGT?

BIGT carries a total expense ratio (TER) of 0.49%, indicating the annual cost for holding the fund.

When was BIGT launched?

BIGT was introduced to the market on January 23, 2018. It trades on Switzerland, among other exchanges

Who is the ETF issuer of BIGT?

L&G Pharma Breakthrough UCITS ETF, BIGT, is provided by L&G. Learn more about L&G here.

What is the current assets under management (AUM) of BIGT?

BIGT oversees €17M in assets as of April 2, 2026.

How has BIGT performed lately?

Based on data from April 2, 2026, BIGT returned 0.16% over the past month, 0.36% over the last three months and 0.51% year-to-date.

What are the latest inflows or outflows for BIGT?

As of April 2, 2026, BIGT recorded net flows of -€569K over the last month and +€15K year-to-date.

Does BIGT distribute dividends?

BIGT follows a capitalizing, meaning it reinvests income within the fund.

What are the main country or region exposures of BIGT?

As of February 28, 2026, BIGT has significant geographic allocations in USA, Japan and Sweden.

In which sector or theme does BIGT invest in?

As of February 28, 2026, BIGT focuses largely on Health Care and Materials.

How many securities does BIGT hold and how diversified is it?

As of February 28, 2026, BIGT holds 36 positions in its portfolio, with 49.53% of assets concentrated in its top 15 holdings.

What are the main positions in BIGT?

As of February 28, 2026, BIGT top three holdings include SWEDISH ORPHAN BIOVITRUM, NIPPON SHINYAKU and CHUGAI PHARMACEUTICAL.

What is the base currency of BIGT?

The base currency of BIGT is USD.

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight